Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

To be part of this study, you need to be between 12 and 65 years old. You must have been diagnosed with systemic lupus erythematosus (SLE) and specifically have severe active lupus nephritis, meaning your kidneys are significantly affected by the lupus. Importantly, your lupus must be considered 'refractory', which means that several standard treatments, including certain strong anti-inflammatory medicines and B cell-targeting therapies, haven't worked well enough for you.

There are also some reasons why you might not be able to join. For example, if you've already had a specific type of treatment for lupus called anti-CD19 therapy. You would also not be able to join if you have serious, lasting damage to your organs from lupus that doctors think would prevent the treatment from helping. Certain other health conditions, ongoing serious infections, a recent history of cancer, or organ transplants would also prevent participation.

If you decide to take part in this study, there are a few stages. First, there's a 'screening period' of about a month where doctors will check if you meet all the requirements. If you do, you'll enter the 'treatment period'. This involves some preparation work, where you'll receive medication to help the obe-cel treatment work better. Then, on 'Day 1' of the treatment period, you'll receive a single infusion of the obe-cel treatment.

After getting the obe-cel infusion, you'll enter the 'post-treatment period', which is all about careful follow-up. You'll have regular hospital visits for various tests, blood samples, and checks to see how you're feeling and how your lupus is responding. The main goal is to check for remission at 6 months, but you will continue to be monitored for your health and the treatment's effects for up to 2 years after your treatment.